Medpace Holdings, Inc.
A contract research organization (CRO), Medpace runs the full span of clinical drug trials — from early safety tests to post-market studies — for small and mid-sized biopharma companies, including medical oversight, monitoring, labs, and regulatory work. Founded in Cincinnati in 1992 by Dr. August Troendle, a former FDA reviewer, it was originally called Medical Research Services; the name Medpace blends "medical" with "pace," reflecting its mission to speed trials along. It also built its own software, ClinTrak, to track studies in real time, and keeps its central labs and a Phase I unit on its own Cincinnati campus.
Granted 780.4K · Bought 1.88M · Sold 6.34M
Granted 221.0K · Bought 1.00M · Sold 4.89M
Granted 200.2K · Bought 19.2K · Sold 174.1K
Granted 252.0K · Sold 274.0K
Granted 36.8K · Sold 9.0K
Granted 135.2K · Bought 2 · Sold 122.8K
Granted 36.6K · Sold 28.6K
Granted 18.8K · Bought 500 · Sold 15.0K
Granted 12.0K · Sold 1.7K
Granted 18.3K
Granted 3.0K
Granted 38.9K · Sold 38.0K
Granted 1.0K · Sold 402
Granted 7.0K · Sold 6.7K
Sold 23.00M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Troendle August J.President & CEO, Director, 10% owner · 267 transactions | — | 10.65M | 780.4K | 1.88M | 6.34M |
| Medpace Investors, LLC10% owner · 214 transactions | — | 4.73Mas of Mar 2024 | 221.0K | 1.00M | 4.89M |
| Burwig Susan EExec. VP, Operations · 34 transactions | — | 70.5K | 200.2K | 19.2K | 174.1K |
| Geiger Jesse JPresident · 41 transactions | — | 46.7K | 252.0K | — | 274.0K |
| Carley Brian TDirector · 19 transactions | — | 27.8K | 36.8K | — | 9.0K |
| Ewald Stephen PGeneral Counsel & Corp. Secy. · 33 transactions | — | 20.3K | 135.2K | 2 | 122.8K |
| Brady Kevin M.CFO & Treasurer · 14 transactions | — | 12.8K | 36.6K | — | 28.6K |
| Davenport Fred B JrDirector · 9 transactions | — | 11.3K | 18.8K | 500 | 15.0K |
| McCarthy Cornelius P. IIIDirector · 17 transactions | — | 10.3K | 12.0K | — | 1.7K |
| Brown BruceDirector · 3 transactions | — | 9.3Kas of May 2019 | 18.3K | — | — |
| Bucknell Penelope JVP, Human Resources · 1 transaction | — | 3.0Kas of May 2017 | 3.0K | — | — |
| Kraft Robert O.Director · 23 transactions | — | 922 | 38.9K | — | 38.0K |
| King Tom CDirector · 4 transactions | — | 598as of May 2022 | 1.0K | — | 402 |
| Keating Ashley M.Director · 15 transactions | — | 250as of May 2024 | 7.0K | — | 6.7K |
| Cinven Capital Management (V) General Partner Ltd +3 co-filers10% owner · 6 transactions | — | 0as of Aug 2018 | — | — | 23.00M |
| Cinven Manco S.A.R.L. +8 co-filers10% owner · 1 transaction | — | 0as of Jun 2017 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -32.00M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.